Living-related liver transplantation and vena cava reconstruction after total hepatectomy including the vena cava for hepatoblastoma

被引:38
作者
Chardot, C
Saint Martin, C
Gilles, A
Brichard, B
Janssen, M
Sokal, E
Clapuyt, P
Lerut, J
Reding, R
Otte, JB
机构
[1] CHU Bicetre, Paris, France
[2] Univ Catholique Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium
关键词
D O I
10.1097/00007890-200201150-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Background. In most cases of total hepatectomy (TH) required for hepatoblastoma (1113), the retrohepatic inferior vena cava (IVC) has to be removed with the native liver for complete tumor excision. Because the liver graft procured by living donation has no IVC, a reconstruction of the recipient IVC is needed. We report our experience with living-related liver transplantation (LRLT) and IVC replacement in such cases. Methods. Between May 1998 and December 1999, four children underwent TH, including IVC and LRLT with IVC replacement for otherwise irresectable HB after chemotherapy (SIOPEL 2 and 3 protocols). IVC reconstruction used an allogenic iliac vein procured from a cadaveric donor (bank graft) in two cases and an internal jugular vein procured from the donor parent in two cases. Median age and weight at surgery were 17 months (range 10-60) and 9.6 kg (range 8.3-17.9). Results. In the living donors, there were two complications of the procurement: one intra-abdominal biliary collection and one subcutaneous abscess. In all four children, complete excision of the tumor could be achieved without any intra-operative complication. One patient died 5 months after LRLT due to lung metastases. Three patients were alive and well with no evidence of tumor recurrence 13-24 months after surgery. Reconstructed IVC was patent in two patients, and asymptomatic thrombosis occurred 2 years after operation in one patient. Conclusion. Total hepatectomy including the retrohepatic IVC is not a technical obstacle to LRLT. Therefore, scheduled surgery, at the best time after chemotherapy, can be considered in all patients with otherwise irresectable HBs.
引用
收藏
页码:90 / 92
页数:3
相关论文
共 17 条
[1]
Al-Qabandi W, 1999, J PEDIATR SURG, V34, P1261
[2]
Pretreatment prognostic factors for children with hepatoblastoma results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1 [J].
Brown, J ;
Perilongo, G ;
Shafford, E ;
Keeling, J ;
Pritchard, J ;
Brock, P ;
Dicks-Mireaux, C ;
Phillips, A ;
Vos, A ;
Plaschkes, J .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) :1418-1425
[3]
Brugieres L, 2000, MED PEDIATR ONCOL, V35, P177
[4]
Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation [J].
Chardot, C ;
Nicoluzzi, JE ;
Janssen, M ;
Sokal, E ;
Lerut, J ;
Otte, JB ;
Reding, R .
TRANSPLANTATION, 2001, 71 (02) :224-229
[5]
Dower NA, 2000, MED PEDIATR ONCOL, V34, P136, DOI 10.1002/(SICI)1096-911X(200002)34:2<136::AID-MPO12>3.0.CO
[6]
2-A
[7]
HEPATOBLASTOMA AND HEPATOCARCINOMA IN CHILDREN - ANALYSIS OF A SERIES OF 29 CASES [J].
GAUTHIER, F ;
VALAYER, J ;
LETHAI, B ;
SINICO, M ;
KALIFA, C .
JOURNAL OF PEDIATRIC SURGERY, 1986, 21 (05) :424-429
[8]
Preserved vascular homograft for revascularization of pediatric liver transplant -: A clinical, histological, and bacteriological study [J].
Martínez, JA ;
Rigamonti, W ;
Rahier, J ;
Gigi, J ;
Lerut, J ;
de Goyet, JD ;
Otte, JB ;
Reding, R .
TRANSPLANTATION, 1999, 68 (05) :672-677
[9]
EFFECTIVENESS AND TOXICITY OF CISPLATIN AND DOXORUBICIN (PLADO) IN CHILDHOOD HEPATOBLASTOMA AND HEPATOCELLULAR-CARCINOMA - A SIOP PILOT-STUDY [J].
NINANE, J ;
PERILONGO, G ;
STALENS, JP ;
GUGLIELMI, M ;
OTTE, JB ;
MANCINI, A .
MEDICAL AND PEDIATRIC ONCOLOGY, 1991, 19 (03) :199-203
[10]
Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group [J].
Ortega, JA ;
Douglass, EC ;
Feusner, JH ;
Reynolds, M ;
Quinn, JJ ;
Finegold, MJ ;
Haas, JE ;
King, DR ;
Liu-Mares, W ;
Sensel, MG ;
Krailo, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2665-2675